They not only have to make it to the postseason but

They not only have to make it to the postseason, but they have to be ready to play four rounds Calgary needs to find a way to sustain the bursts of brilliance they've demonstrated sporadically throughout the year. Success will mean utilising the impressive arsenal at Calgary’s disposal and digging deep to find the drive that all four lines will need to play consistently. Several leaders inthe field supported the notion of huge potential for ApoA-I to treatatherosclerosis and cardiovascular disease.In a second keynote address during the same ACC conference Dr. Prediman K.Shah, Director of the Division of Cardiology and the Atherosclerosis ResearchCenter at Cedars-Sinai Medical Center highlighted the advances of RVX-208during his presentation titled "Novel strategies to increase HDL" During hispresentation, Dr. Shah reviewed the unique features of RVX-208's novelmechanism of action and properties by which ApoA-I and functional HDL areincreased.Resverlogix continues to expand its scientific leadership throughparticipation in key scientific conferences including presenting data on April30, 2009 during the AHA Arteriosclerosis, Thrombosis and Vascular BiologyAnnual conference. On June 18, 2009 Resverlogix will be participating in aworkshop that examines therapies which enhance reverse cholesterol transportduring the XV International Symposium on Atherosclerosis hosted by theInternational Atherosclerosis Society.Resverlogix granted 1,430,000 stock options to new employees, officers anddirectors and existing employees whose options expired during an extensiveblackout period. During the past fiscal year 1,483,900 option grants expired,of which all director and officers expired options were priced below currentmarket value.

Given the expiry of these options, the new grant has a neutraleffect on the capital structure of the company. The stock options planprovides for the issuance of up to a maximum of 10% of the issued andoutstanding common shares. Subsequent to this option grant, the total optionsoutstanding is equal to 6.9% of the issued and outstanding common shares andwas 4.7% prior to the recent financing.About RVX-208RVX-208, a novel small molecule therapeutic that facilitates endogenous ApoA-Iproduction, is positioned to be one of the most promising emerging drugs inthe treatment of atherosclerosis. To the Company's knowledge RVX-208 is theonly novel small molecule that is specifically designed to increase ApoA-Iproduction and thereby raise HDL levels thus enhancing HDL functionality toaugment reverse cholesterol transport.About Resverlogix Corp.Resverlogix Corp. is a leading biotechnology company engaged in thedevelopment of novel therapies for important global medical markets withsignificant unmet needs. The NexVas(TM) PR program is the Company's primaryfocus which is to develop novel small molecules that enhance ApoA-I.

Thesevital therapies address the grievous burden of atherosclerosis and otherimportant diseases such as Acute Coronary Syndrome, Diabetes, Alzheimer'sdisease, Peripheral Artery Disease and other vascular disorders ResverlogixCorp trades on the Toronto Stock Exchange (TSX:RVX). For further informationplease visit news release may contain certain forward-looking statements that reflectthe current views and/or expectations of Resverlogix Corp with respect to itsperformance, business and future events. Such statements are subject to anumber of risks, uncertainties and assumptions Actual results and events mayvary significantly. The TSX Exchange does not accept responsibility for theadequacy or accuracy of this news release.SOURCEResverlogix Corp.Theresa Kennedy, VP, Corporate Communications, Resverlogix Corp., Phone: (604)538-7072, Fax: (403) 256-8495, Email: ; DonaldMcCaffrey, President & CEO, Resverlogix Corp., Phone: (403) 254-9252, Fax:(403) 256-8495, Email: .

Okay, who called these upsets?  March just got a little madder, as two No 13 seeds and two No 12 seed have won. But as we size up our brackets, let's not lose sight of the more compelling question:How did the fab freshman do in their first NCAA experience?  Of the first 14 picks in the NBA Draft, seven are predicted to be freshman and of those top players, four won in the first round of the Tournament and three lost.Likely top pick Michael Beasley led all scorers with 23 points and 11 rebounds.  He beat USC and the country's other top freshman, O.J. Mayo.  Mayo scored 20 points and dished out five assists in the loss.Memphis' Derrick Rose won his first game, as he scored 17 points and made six of his 10 shots from the field.  Also on the winning end was Blake Griffin, who scored 12 points and only missed one shot all day as Oklahoma beat St. ultimately land and how they fare at the next level. .